Actavis buying Durata Therapeutics for $616.4M

SHARE Actavis buying Durata Therapeutics for $616.4M

Specialty pharmaceutical company Actavis is buying Chicago-based Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. One of Durata’s key products is Dalvance for injection, an IV antibiotic for acute bacterial skin and skin structure infections. Dalvance was approved by the Food and Drug Administration in May.

Read more at Newsfeed.

The Latest
In fur and makeup, Jesse Eisenberg and Riley Keough spend most of the movie scratching, sneezing and worse.
The Hawks weren’t able to translate possession time into much tangible offense during a 3-1 loss Tuesday in Vegas.
A hazardous weather outlook, bringing gusty winds and showers, was in effect in Cook County on Tuesday evening, as well as much of northern Illinois and parts of northwest Indiana through midnight.
Sitting at Nos. 1 and 9, Bears general manager Ryan Poles has a huge opportunity next week.